論文

査読有り
2020年5月28日

Current status of immune checkpoint inhibitors for gastric cancer.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • Koji Kono
  • ,
  • Shotaro Nakajima
  • ,
  • Kosaku Mimura

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s10120-020-01090-4

Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with ICI including nivolumab and pembrolizumab has been emerging as a novel treatment strategy for advanced gastric cancers (GC). In a meta-analysis for anti-PD-1/PD-L1 therapy in GC, the objective response rate was 12.0% and the disease control ratio was 34.7%. The ICI treatment in GC provided modest survival benefit and especially, anti-PD-1 treatment could improve the 12-month and 18-month overall survival rate and prolonged the duration of the response. Moreover, it is likely that anti-PD-1/PD-L1 therapy is more effective in subgroups with microsatellite instability-high, Epstein-Barr virus-positive or high mutation burden in advanced GC. The next steps for developing ICI in GC are mainly two challenges as follows. First is the identification of accurate biomarkers that can predict the response to ICI. The second challenge is the clinical development of combinatorial approaches to maximize the efficacy of ICI. In this review, recent advances in ICI for GC are discussed from a viewpoint of translational aspect including biomarkers and tumor microenvironment, and from a viewpoint of clinical aspects including combination therapies.

リンク情報
DOI
https://doi.org/10.1007/s10120-020-01090-4
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32468420
ID情報
  • DOI : 10.1007/s10120-020-01090-4
  • PubMed ID : 32468420

エクスポート
BibTeX RIS